Manufacturer record
Hindustan Antibiotics Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
37 batches manufactured by Hindustan Antibiotics Ltd (Haryana) were declared Not of Standard Quality between October 2019 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
37 records linked to Hindustan Antibiotics Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
37Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
37
NSQ batches since 2019
21
Products affected
Dissolution
Most common failure
Jun 2026
Latest alert
Flagged batches per year
2019 · 22020 · 12021 · 42022 · 72023 · 52024 · 72025 · 82026 · 3
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Atorvastatin Tablets IP 20mg | 0062Mfg 2025-07 · Exp 2027-06 | The sample does not conform to claim as per IP 2022 in respect to test of Related substances.Related substances | RDTL, ChandigarhCDSCO lab | Jun 2026 |
| Albendazole Tablets IP 400 mg | 0112Mfg 2025-01 · Exp 2026-12 | The sample does not conform to I.P. with respect to test for Dissolution.Dissolution | CDL, KolkataCDSCO lab | Jan 2026 |
| Albendazole Tablets IP 400 mg | APR-00Mfg 2025-01 · Exp 2026-12 | The sample does not conform to I.P. with respect to test for Dissolution.Dissolution | SDT&RL, BhubaneswarState lab | Jan 2026 |
| Ciprofloxacin Tablets IP 500mg | 2140Mfg 2023-01 · Exp 2025-12 | Failed Description (Rough Surface)Description | DTL, PuducherryState lab | Dec 2025 |
| Ceftriaxone Injection I.P. 1 g | HCBA19Mfg 2023-08 · Exp 2025-07 | Clarity of solution, Particulate Matter, DescriptionDescription | CDL, KolkataCDSCO lab | Aug 2025 |
| Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg | BT240754Mfg 2024-06 · Exp 2026-05 | Dissolution of Amoxycillin, Water, Dissolution of Clavulanic Acid and Assay of Potassium ClavulanteAssay | CDL, KolkataCDSCO lab | Jul 2025 |
| Cefotaxime Sodium Injection IP 1g | 1172Mfg 2023-08 · Exp 2025-07 | WaterWater content | CDL KolkataCDSCO lab | Jun 2025 |
| Pantoprazole Tablets IP 40 mg | 92Mfg 2024-07 · Exp 2026-06 | Dissolution and DescriptionDissolution | CDL, KolkataCDSCO lab | May 2025 |
| Amoxycillin and potassium clavulanate tablets IP 625 mg | BT240491Mfg 2024-05 · Exp 2026-04 | Sample does not conform to IP specification for amoxycillin and potassium clavulanate tablets with respect to the content of Clavulanic acid in potassium clavulanate.Other | DTL MaduraiState lab | Apr 2025 |
| Pantoprazole tablets IP 40 mg | 81Mfg 2024-05 · Exp 2026-04 | Dissolution (Buffer Stage)Dissolution | CDL, KolkataCDSCO lab | Mar 2025 |
| Atorvastatin Tablets IP 10 mg | 57Mfg 2024-09 · Exp 2026-08 | "Related substances"Related substances | CDTL-MumbaiCDSCO lab | Mar 2025 |
| DOXYCYCLINE CAPSULES IP 100 mg | HDXA08Mfg 2023-06 · Exp 2025-05 | "Uniformity of weight"Uniformity of weight/content | CDTL MumbaiCDSCO lab | Dec 2024 |
| Ornidazole & Ofloxacin Tablets IP | HOOA07Mfg 2023-08 · Exp 2025-07 | DescriptionDescription | CDL KolkataCDSCO lab | Oct 2024 |
| Metronidazole Tablets I.P. 400 mg | HMAA04Mfg 2023-07 · Exp 2025-06 | DissolutionDissolution | CDL KolkataCDSCO lab | Sep 2024 |
| Diclofenac Sodium Tablets IP 50 mg | HDFA02Mfg 2023-11 · Exp 2025-10 | DissolutionDissolution | CDL KolkataCDSCO lab | Sep 2024 |
| Metronidazole Tablets IP 400mg | HMAA04Mfg 2023-07 · Exp 2025-06 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Aug 2024 |
| Compound Sodium Lactate Injection IP (Ringers Lactate Solution for Injection) | 2918Mfg 2022-12 · Exp 2025-11 | Bacterial EndotoxinsBacterial endotoxins | RDTL ChandigarhCDSCO lab | Jul 2024 |
| Losartan Potassium Tablets IP 50 mg | HLOA06Mfg 2023-11 · Exp 2025-10 | It fails the test ?Dissolution? as per IPDissolution | DTL ThiruvananthapuramState lab | Jun 2024 |
| Omeprazole Capsules IP 20 mg | C22G004Mfg 2022-07 · Exp 2024-06 | Dissolution & Loss on DryingDissolution | CDL KolkataCDSCO lab | Sep 2023 |
| Ornidazole & Ofloxacin Tablets IP | HOOZ01Mfg 2022-07 · Exp 2024-06 | DescriptionDescription | CDL KolkataCDSCO lab | Jul 2023 |
| Paracetamol Tablets I.P. 650 mg | 19Mfg 2023-01 · Exp 2024-12 | DissolutionDissolution | CDL KolkataCDSCO lab | Jun 2023 |
| CETIRIZINE TABLETS IP 10 mg | 51Mfg 2022-05 · Exp 2024-04 | Related substancesRelated substances | CDTL MumbaiCDSCO lab | Jun 2023 |
| Diclofenac Sodium Injection IP | DSIY-85Mfg 2021-12 · Exp 2023-11 | Particulate MatterParticulate matter | RDTL ChandigarhCDSCO lab | Apr 2023 |
| Calcium and Vitamin D3 Tablets I.P. (500 mg + 250 IU) | CWTY-201Mfg 2021-12 · Exp 2023-11 | Description, Dissolution of Calcium & Assay of Vitamin D3Assay | CDL KolkataCDSCO lab | Nov 2022 |
| LEVOCETIRIZINE TABLETS IP. 5 mg. | 70Mfg 2021-12 · Exp 2023-11 | DescriptionDescription | RDTL GuwahatiState lab | Oct 2022 |
| Ibuprofen Tablets I.P. 400 mg | IDTY-04Mfg 2021-06 · Exp 2023-05 | Assay & DissolutionAssay | CDL KolkataCDSCO lab | Jun 2022 |
| Doxycycline Capsules I.P. 100 mg | DXCY-02Mfg 2021-05 · Exp 2023-04 | AssayAssay | CDL KolkataCDSCO lab | Mar 2022 |
| Calcium and Vitamin D3 Tablets IP (500 mg + 250 IU) (Calcium 500 mg & Vitamin D3 250 IU) | CWTY-103Mfg 2021-02 · Exp 2023-01 | Dissolution & Assay of Vitamin D3Assay | CDL KolkataCDSCO lab | Mar 2022 |
| Ranitidine Tablets IP 150 mg. | NSTX-11Mfg 2020-11 · Exp 2022-10 | DescriptionDescription | RDTL GuwahatiCDSCO lab | Feb 2022 |
| Cetirizine Syrup I.P. 5 mg / 5 ml ? 60ml | L2106027Mfg 2021-06 · Exp 2023-05 | Description & pHDescription | CDL KolkataCDSCO lab | Feb 2022 |
| Ranitidine Tablets IP 150 mg | NSTY-05Mfg 2021-06 · Exp 2023-05 | Uniformity of weightUniformity of weight/content | CDTL MumbaiCDSCO lab | Oct 2021 |
| CEFUROXIME AXETIL TABLETS IP 500 MG | XATX-01Mfg 2020-07 · Exp 2022-06 | DissolutionDissolution | RDTL ChandigarhCDSCO lab | Oct 2021 |
| Diclofenac Sodium Inj. I.P. 75 mg/ 3ml | DSIX-109Mfg 2020-12 · Exp 2022-11 | Particulate MatterParticulate matter | CDL KolkataCDSCO lab | Jun 2021 |
| Paracetamol Tablets IP 500 mg | 999Mfg 2019-03 · Exp 2022-02 | DissolutionDissolution | CDTL ChennaiCDSCO lab | May 2021 |
| Cefotaxime Sodium Injection IP 250 mg | 0322Mfg 2019-07 · Exp 2021-06 | WaterWater content | CDL KolkataCDSCO lab | Jun 2020 |
| Compound Sodium Lactate Injection IP (Ringers Lactate Solution for Injection) | 2198Mfg 2019-01 · Exp 2021-12 | Description & SterilityDescription | CDTL ChennaiCDSCO lab | Oct 2019 |
| Ciprofloxacin Tablets IP 500 mg | 2095Mfg 2019-11 · Exp 2021-12 | DissolutionDissolution | RDTL ChandigarhCDSCO lab | Oct 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.